CARIS LIFE SCIENCES, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $812.0M | $412.3M | $306.1M |
| Cost of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin | — | — | — |
| Operating Expenses | |||
| Research & Development | $101.6M | $113.9M | $116.9M |
| SG&A Expense | $225.0M | $169.4M | $149.1M |
| Operating Income | $45.1M | $-257.1M | $-319.6M |
| Operating Margin | 5.6% | -62.4% | -104.4% |
| Interest Expense | $56.8M | $50.0M | $31.5M |
| Pretax Income | $-68.1M | $-281.9M | $-341.4M |
| Income Tax Expense | $0 | $0 | $0 |
| Net Income | $-68.1M | $-281.9M | $-341.4M |
| Net Margin | -8.4% | -68.4% | -111.5% |
| EPS (Basic) | $-3.22 | $-2.13 | $-2.65 |
| EPS (Diluted) | $-3.22 | $-2.13 | $-2.65 |
| Shares Outstanding (Basic) | 167.2M | 177.5M | 174.7M |
| Shares Outstanding (Diluted) | 167.2M | 177.5M | 174.7M |
| Dividends Per Share | — | — | — |